Dainipponn Sumitomo Pharma Co.

Ōsaka, Japan

Dainipponn Sumitomo Pharma Co.

Ōsaka, Japan
SEARCH FILTERS
Time filter
Source Type

Hur J.-Y.,Karolinska Institutet | Teranishi Y.,Karolinska Institutet | Teranishi Y.,Dainipponn Sumitomo Pharma Co. | Kihara T.,Karolinska Institutet | And 10 more authors.
Journal of Biological Chemistry | Year: 2012

In Alzheimer disease, oligomeric amyloid β-peptide (Aβ) species lead to synapse loss and neuronal death. γ-Secretase, the transmembrane protease complex that mediates the final catalytic step that liberates Aβ from its precursor protein (APP), has a multitude of substrates, and therapeutics aimed at reducing Aβ production should ideally be specific for APP cleavage. It has been shown that APP can be processed in lipid rafts, and γ-secretase- associated proteins can affect Aβ production. Here, we use a biotinylated inhibitor for affinity purification of γ-secretase and associated proteins and mass spectrometry for identification of the purified proteins, and we identify novel γ-secretase-associated proteins in detergent-resistant membranes from brain. Furthermore, we show by small interfering RNA-mediated knockdown of gene expression that a subset of the γ-secretase-associated proteins, in particular voltage-dependent anion channel 1 (VDAC1) and contactin-associated protein 1 (CNTNAP1), reduced Aβ production (Aβ40 and Aβ42) by around 70%, whereas knockdown of presenilin 1, one of the essential γ-secretase complex components, reduced Aβ production by 50%. Importantly, these proteins had a less pronounced effect on Notch processing. We conclude that VDAC1 and CNTNAP1 associate with γ-secretase in detergent-resistant membranes and affect APP processing and suggest that molecules that interfere with this interaction could be of therapeutic use for Alzheimer disease. © 2012 by The American Society for Biochemistry and Molecular Biology, Inc.

Loading Dainipponn Sumitomo Pharma Co. collaborators
Loading Dainipponn Sumitomo Pharma Co. collaborators